Abstract
In the original article, there was a mistake in Figure 1 as published. The colors of the labels used for Figures 1B,D were incorrect. pCR should be in red and non-pCR should be in blue. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. (Figure Presented).
Cite
CITATION STYLE
Pernas, S., Petit, A., Climent, F., Paré, L., Perez-Martin, J., Ventura, L., … Prat, A. (2019, September 1). Corrigendum: PAM50 subtypes in baseline and residual tumors following neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer: A consecutive-series from a single institution (Front. Oncol. (2019), 9, 707, 10.3389/fonc.2019.00707). Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2019.00967
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
